Ribosome Display Technology
Ribosome display technology is a superior platform for in vitro molecular evolution of antibody affinity developed by Drs Mike Taussig and Mingyue He at the Babraham Institute. It has advantages based on the very high library diversity that can be achieved, and the fact that the entire process is performed rapidly in vitro. Crescendo owns IP for eukaryotic ribosome display, and has developed a robust process for optimisation of VH fragments produced from its transgenic platforms.
Click image for larger version
